A False Discovery Rate Procedure for Categorical Data

Author(s):  
Joseph F. Heyse
2000 ◽  
Vol 279 (1) ◽  
pp. R1-R8 ◽  
Author(s):  
Douglas Curran-Everett

Statistical procedures underpin the process of scientific discovery. As researchers, one way we use these procedures is to test the validity of a null hypothesis. Often, we test the validity of more than one null hypothesis. If we fail to use an appropriate procedure to account for this multiplicity, then we are more likely to reach a wrong scientific conclusion—we are more likely to make a mistake. In physiology, experiments that involve multiple comparisons are common: of the original articles published in 1997 by the American Physiological Society, ∼40% cite a multiple comparison procedure. In this review, I demonstrate the statistical issue embedded in multiple comparisons, and I summarize the philosophies of handling this issue. I also illustrate the three procedures—Newman-Keuls, Bonferroni, least significant difference—cited most often in my literature review; each of these procedures is of limited practical value. Last, I demonstrate the false discovery rate procedure, a promising development in multiple comparisons. The false discovery rate procedure may be the best practical solution to the problems of multiple comparisons that exist within physiology and other scientific disciplines.


Genetics ◽  
2003 ◽  
Vol 164 (2) ◽  
pp. 829-833
Author(s):  
Chiara Sabatti ◽  
Susan Service ◽  
Nelson Freimer

Abstract We explore the implications of the false discovery rate (FDR) controlling procedure in disease gene mapping. With the aid of simulations, we show how, under models commonly used, the simple step-down procedure introduced by Benjamini and Hochberg controls the FDR for the dependent tests on which linkage and association genome screens are based. This adaptive multiple comparison procedure may offer an important tool for mapping susceptibility genes for complex diseases.


2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii71-iii71
Author(s):  
T Kaisman-Elbaz ◽  
Y Elbaz ◽  
V Merkin ◽  
L Dym ◽  
A Noy ◽  
...  

Abstract BACKGROUND Glioblastoma is known for its dismal prognosis though its dependency on patients’ readily available RBCs parameters defining the patient’s anemic status such as hemoglobin level and Red blood cells distribution Width (RDW) is not fully established. Several works demonstrated a connection between low hemoglobin level or high RDW values to overall glioblastoma patient’s survival, but in other works, a clear connection was not found. This study addresses this unclarity. MATERIAL AND METHODS In this work, 170 glioblastoma patients, diagnosed and treated in Soroka University Medical Center (SUMC) in the last 12 years were retrospectively inspected for their survival dependency on pre-operative RBCs parameters using multivariate analysis followed by false discovery rate procedure due to the multiple hypothesis testing. A survival stratification tree and Kaplan-Meier survival curves that indicate the patient’s prognosis according to these parameters were prepared. RESULTS Beside KPS>70 and tumor resection supplemented by oncological treatment, age<70 (HR=0.4, 95% CI 0.24–0.65), low hemoglobin level (HR=1.79, 95% CI 1.06–2.99) and RDW<14% (HR=0.57, 95% CI 0.37–0.88) were found to be prognostic to patients’ overall survival in multivariate analysis, accounting for false discovery rate of less than 5%. CONCLUSION A survival stratification highlighted a non-anemic subgroup of nearly 30% of the cohort’s patients whose median overall survival was 21.1 months (95% CI 16.2–27.2) - higher than the average Stupp protocol overall median survival of about 15 months. A discussion on the beneficial or detrimental effect of RBCs parameters on glioblastoma prognosis and its possible causes is given.


2020 ◽  
Vol 223 (1) ◽  
pp. 19-22
Author(s):  
Jingjing Zhu ◽  
Chong Wu ◽  
Lang Wu

Abstract It is critical to identify potential causal targets for SARS-CoV-2, which may guide drug repurposing options. We assessed the associations between genetically predicted protein levels and COVID-19 severity. Leveraging data from the COVID-19 Host Genetics Initiative comparing 6492 hospitalized COVID-19 patients and 1 012 809 controls, we identified 18 proteins with genetically predicted levels to be associated with COVID-19 severity at a false discovery rate of &lt;0.05, including 12 that showed an association even after Bonferroni correction. Of the 18 proteins, 6 showed positive associations and 12 showed inverse associations. In conclusion, we identified 18 candidate proteins for COVID-19 severity.


Sign in / Sign up

Export Citation Format

Share Document